.png){kind=icon}
返回
Profound dFLC decrease after one cycle predicts superior outcome in patients with AL amyloidosis
.png){kind=icon}
PRE
AI
DOI：10.1080/10428194.2025.2571200.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
早期游离轻链差值（dFLC）下降与AL淀粉样变性患者的临床结局关系显著。我们开展了一项多中心研究（n=86，基线dFLC≥50 mg/L），所有患者均接受一线daratumumab-bortezomib治疗方案。ROC分析显示，一个疗程后的dFLC下降（87%降幅，AUC=0.82）可预测完全血液学缓解（CHR）。一个疗程后达到>87% dFLC降幅或非常好的部分缓解的患者被归类为最佳应答者（O-HR），而未达此标准者被归类为非最佳应答者（S-HR）。O-HR组的CHR率（90.5% vs 43.5%，p<0.001）、心脏应答率（68.9% vs 36.8%，p=0.017）和肾脏应答率（76.6% vs 50.0%，p=0.045）均高于S-HR组。一个疗程后的显著dFLC下降提示高CHR和器官应答的可能性，支持早期调整治疗方案。
Keyword:
AL amyloidosis
difference between the involved and uninvolved free light chain
early response
期刊
L
IF:
2.2
论文数:
238
被引数:
0
机构
引用论文
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateAL淀粉样变性的治疗: 骨髓瘤的Mayo分层和风险适应治疗 (mSMART) 共识声明2020更新
OAAI
OAAI分享收藏Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.png)
Blood
OAAI
BloodIF0
OAAI分享收藏Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis基于Daratumumab的免疫球蛋白轻链淀粉样变性的治疗OAAI
OAAI分享收藏Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosisOAAI
OAAI分享收藏Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosisBLOOD CANCER JOURNALOAAI
BLOOD CANCER JOURNALIF11.6
OAAI分享收藏Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group非移植化疗治疗系统性AL淀粉样变性的指南: eha-isa工作组OAAI
OAAI分享收藏Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDADaratumumab联合硼替佐米，环磷酰胺和地塞米松在亚洲新诊断的AL淀粉样变性患者中的应用: 仙女座的亚组分析ANNALS OF HEMATOLOGYOAAI
ANNALS OF HEMATOLOGYIF2.4
OAAI分享收藏
查看更多内容